symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CYBN,0.5364,1.602419,4346792,131414248,0,0.21-0.715,-0.0356,Cybin Inc.,USD,0001833141,CA23256X1006,23256X100,American Stock Exchange,AMEX,Biotechnology,https://www.cybin.com,"Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.","Mr. Eric  So L.L.B., LLB",Healthcare,CA,50,908 764 8385,100 King Street West,Toronto,ON,M5X 1C9,,0,https://financialmodelingprep.com/image-stock/CYBN.png,2019-09-13,False,False,True,False,False
